openPR Logo

Press Releases from Kuick Resarch (821 total)

Global Breast Cancer Predictive Genetic Testing Market Offers Billion Dollars Op …

“Global Breast Cancer Predictive Genetic Testing Market Outlook 2022” Report Highlights: * Hereditary Breast Cancer Genes * Conceptual of Breast Cancer Susceptibility * Predictive Cancer Testing Essentials * Economical, Ethical and Social Aspects * Global Prevalence of Breast Cancer * Market and Cost Analysis of Predictive Testing * Insurance Affairs for Breast Cancer Predictive Testing For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report: https://www.kuickresearch.com/report-global-breast-cancer-predictive-genetic-testing-market-outlook-2022.php Report Table of Contents Cancer Susceptibility Testing 1.1 Prologue to Cancer Susceptibility

Transdermal Patch Market Witnessing Exponential Growth With 79 Patches in Clinic …

“Global Transdermal Patch Market and Clinical Pipeline Outlook 2022” report highlights: * Introduction and Classification of Transdermal Patch * Mechanism of Transdermal Patch Drug Delivery * Transdermal Patch v/s Traditional Drug Delivery Methods * Global Transdermal Patch Clinical Pipeline Overview * Marketed Transdermal Patch Clinical Insight by Company, Indication and Phase * Global Transdermal Patch Market Future Prospects For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report: https://www.kuickresearch.com/report-global-transdermal-patch-market-and-clinical-pipeline-outlook-2022.php Report Table of Contents Introduction to Transdermal Patch Classification of

Global Immune Check Point Inhibitors Clinical Pipeline Has 79 Drugs In Pipeline

Global Immune Check Point Inhibitors Market and Clinical Pipeline Insight 2022” report highlights: * Introduction and Mechanism of Action of Immune Checkpoint Inhibitors * CTLA 4, PD-1 and PD-L1 Inhibition Approved Drugs to Target Immune Checkpoints * Biomarkers Associated with Immune Checkpoint Inhibitors * Combination Approaches with Immune Checkpoint Inhibitors * Global Immune Checkpoint Inhibitors Clinical Pipeline * Future Potential of Immune Checkpoint Inhibitors For Report Sample Contact: neeraj@kuickresearch.com or

China To Dominate Global High Speed Rail Investments

“China High Speed Rail Sector and Investment Opportunity Analysis” report gives comprehensive insight on the current and future development scenario related to high speed rail network in China. Report discusses and analyzes the ongoing transformation in the overall rail passenger rail travel in China due to emergence and exponential growth in the high speed rail network over the last decade. Currently China has emerged as the predominant player in the

Middle East Railway Sector To Witness USD 200 Billion Investments By 2030

“Middle East Railway Sector and Investment Opportunity Analysis” report gives comprehensive insight on the current scenario of rail transport in Middle East region at country level. Report also discusses the policy and regulatory framework adopted by each country along with the initiatives undertaken by the various stakeholders to promo the growth of rail network in the region. Currently Iran, Turkey, Egypt and Saudi Arabia are the dominant players in

Saudi Arabia Airport Privatization To Transform Regional Civil aviation Sector

“Saudi Arabia Airport Privatization Opportunity Outlook 2022” report highlights: * Saudi Arabia Aviation Industry Overview * Privatization in Saudi Arabia * Investment and Expansion Opportunities for International Investors * Civil Aviation Laws and Policies Framework * Ongoing Privatization Projects * Privatization Build - Operateandndash;Transfer (BOT) Business Model For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report: https://www.kuickresearch.com/report-saudi--arabia--airport--privatization--opportunity--outlook--2022.php Report Table of Contents Saudi Arabia Aviation Industry Overview Privatization in Saudi Arabia Saudi Arabia Civil

Sri Lanka Mutual Fund Sector preforming Health Growth Of 10% In Recent Years

“Sri Lanka Mutual Fund Sector Opportunity Outlook 2022” report highlights: * Sri Lanka Financial Sector Overview * Sri Lanka Unit Trust/Mutual Fund Market Overview * Types of Unit Trusts/ Mutual Funds * Funds and Fund Managers * Rules for Unit Trust/ Mutual Fund Companies For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report: https://www.kuickresearch.com/report-sri-lanka-mutual-fund-market-opportunity-outlook-2022.php Report Table of Contents What are Unit Trusts (Mutual Fund)? Types of Unit Trusts (Mutual Funds) in Sri Lanka 2.1 Types of Funds

US To Dominate Global Antidiabetics Drug Market

“US Antidiabetics Drug Market Outlook 2022” report highlights: * US Diabetes Epidemiology * US Antidiabetics Market Overview * Key Marketed Antidiabetic Drugs in US * US Biosimilar Insulin Market * US Antidiabetics Drug Market Future Prospects For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report: https://www.kuickresearch.com/report-us-antidiabetics-drug-market-outlook-2022.php Report Table of Contents Antidiabetics: Regimen for Diabetes Mellitus 1.1 Prologue Towards Diabetes 1.2 Preface to Antidiabetics Antiquity of Managing Diabetes Mellitus 2.1 Trajectory from Diabetes to Insulin

Global Rheumatoid Arthritis Drug Market To Surpass USD 25 Billion in 2017

“Global Rheumatoid Arthritis Drug Market Outlook 2022” report highlights: * Classification and Molecular Mechanism of Rheumatoid Arthritis Drugs * Synthetic DMARDs as Rheumatoid Arthritis Drug * Biological Agents as Rheumatoid Arthritis Drug * Global Market of Rheumatoid Arthritis Drug * Global Tendencies in Use of Antirheumatics * Global Rheumatoid Arthritis Drug Market Future Prospect For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report: https://www.kuickresearch.com/report-global-rheumatoid-arthritis-drug-market-outlook-2022.php Report Table of Contents Antirheumatoids: Call of Rheumatoid Arthritis 1.1 Prologue towards Rheumatoid Arthritis

US Cancer Generics Market To Witness Exponential Growth With Launch Of Various P …

“US Cancer Generics Market Outlook 2022” report highlights: * Introduction to Cancer Generics * US Generic Drugs Legislature * US Health Insurance Scenario and Cancer * Aspects of Branded and Non-Branded Generics * US Cancer Generics Market Overview For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report: https://www.kuickresearch.com/report-us-cancer-generics-market-outlook-2022.php Report Table of Contents Cancer Generics: A Modest Regimen 1.1 Introduction to Cancer Generics 1.2 Why There Exist is Need for Generic Forms? 1.3 Supremacy of Cancer

Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …

“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of

Global Lung Cancer Vaccine Clinical Trials Have 30 Vaccines In Pipeline

“Global Lung Cancer Vaccine Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global lung cancer vaccine market. Currently there are 3 lung cancer vaccines commercially available in the market. This report analyzes the ongoing clinical trial of 30 lung cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the lung cancer vaccines. Currently there are

Personalized Cancer Vaccines Transforming Global Cancer Vaccines Market With Per …

The report “Personalized Cancer Vaccines Market and Clinical Innovation Outlook 2022” is an inclusive report which covers the current and future opportunities for the personalized cancer vaccines and its varied inclinations in oncology. The report throws a light over the clinical relevance of personalized forms and identifies the risk and commercial aspects along with the potential outcome for the success of personalized cancer vaccines in the upcoming future directions. For Report

Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …

“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic

Global Breast Cancer Vaccine Treatment Offers Billion Dollars Opportunity For Va …

“Global Breast Cancer Vaccine Market and Clinical Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global breast cancer vaccine development market. Currently there is no single breast cancer vaccine commercially available in the market. This report analyzes the ongoing clinical trial of 36 breast cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the vaccine. Most of

Cancer Nanomedicine Market Offers Opportunity With 8 Drugs In Market and 124 Dru …

“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights: * Overview and Mechanism of Action of Nanomedicine * Nanomedicine Engineering: Design and Strategy * Cancer Nanomedicine as Diagnostic and Therapeutics Tool * Global Cancer Nanomedicine Market Overview and Dynamics * Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase * Global Cancer Nanomedicine Clinical Pipeline: 124 Drug * Marketed Cancer Nanomedicine: 8 Drugs For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report: https://www.kuickresearch.com/report-global-cancer-nanomedicine-market-outlook-2022.php Report Table of Contents Cancer Nanomedicine: An Optimistic

Tumor Necrosis Factor Inhibitors Market To Double In Decade With 151 TNF Inhibit …

“Tumor Necrosis Factor Inhibitors Market and Clinical Pipeline Outlook 2022” Report Highlight: * Overview of Tumor Necrosis Factor Inhibitors * Approaches Used in Development of Anti-TNF * TNF Inhibitors Market Overview * Tumor Necrosis Factor as an Anti-Cancer Agent * Global Tumor Necrosis Factor Inhibitors Pipeline by Company, Indication and Phase * Global Tumor Necrosis Factor Inhibitors Pipeline: 151 * Marketed Tumor Necrosis Factor Inhibitors: 25 For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report: https://www.kuickresearch.com/report-tumor-necrosis-factor-inhibitors-market-and-clinical-pipeline-outlook-2022.php Report Table of

CAR T Cell Therapy To Dominate Emerging Cancer Therapy Treatment Market With 100 …

“Global CAR T Cell Therapy Market and Clinical Trials Insight 2022” report highlights: * CAR T Cell Therapies Delivery Pipeline and Mechanism of Action * Global CAR T Cell Therapy Clinical Trials for Cancer Treatment * Global CAR T Cell Therapies Clinical Pipeline by Company, Indication and Phase * Global CAR T Cell Therapies Clinical Pipeline: 99 Therapies * CAR T Cell Therapies in Highest Phase: Preregistration * Majority of CAR T Cell

Global Dendritic Cell Cancer Vaccine To Transform Cancer Therapy Market Landscap …

“Global Dendritic Cell Cancer Vaccine Market and Clinical Trials Outlook 2023” Highlights: * Global Dendritic Cell Cancer Vaccine Market Overview * Assessment of Dendritic Vaccines with Other Therapeutic Regimens * Global Dendritic Cell Vaccines Clinical Pipeline by Company, Indication and Phase * Marketed Dendritic Cell Vaccines Clinical Insight * Dendritic Cells Mechanizing Immune Response * Future Growth Opportunities For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report: https://www.kuickresearch.com/report-global-dendritic-cell-cancer-vaccine-market-and-clinical-trials-outlook-2023.php Report Table of Contents 1. Advent of Dendritic Vaccine in

Global Hepatitis Drug Market To Surpass USD 70 Billion by 2023

“Global Hepatitis Drug Market and Clinical Trials Insight 2023” report highlights: * Prevalence of Hepatitis Infection * Available Drug Classes for Hepatitis Drug * Global Hepatitis Drug Market Analysis * Global Hepatitis (A,B,C,D and E) Drug Clinical Pipeline Insight * Marketed Hepatitis Drug Clinical Insight by Drug Class * Future Perspective of Hepatitis Therapeutics For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report: https://www.kuickresearch.com/report-global-hepatitis-drug-market-and-clinical-trials-insight-2023.php Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue

Global Immune Check Point Inhibitors Market & Immune Check Point Inhibitors Clin …

Immunotherapy represents a paradigm shift in oncology therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity. The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab

Tumor Necrosis Factor Inhibitors Market & TNF Inhibitors Clinical Pipeline Outlo …

The search for the effective therapeutic approaches in the modulation of the TNF has been focus of the research efforts. Approximately 1 Million people in the worldwide either undergoing the treatment or have been treated with the TNF inhibitors which are available in the pharmaceutical market which surrounding the indications that include the rheumatoid arthritis, psoriatic arthritis, psoriasis and inflammatory bowel diseases. The neutralization of the TNF signaling can be achieved

Saudi Arabia Mutual Fund Market & Assets Opportunity Outlook 2022

Saudi Arabia holds the largest mutual fund industry in Arab world. Saudi Mutual funds are one of the market sectors is one of the few that moved in a correct order for the industrial direction adding to some stability of market growth. This is due to the fact that mutual funds are managed by professionals and authorized managers and are closely performed according to fund structure and investment guidelines.

Global Nano Chemotherapy Drug Market & Nano Chemotherapy Clinical Trials Outlook …

The growing interest in the field of medical application of nanotechnology by academic and industrial researchers worldwide has led to the development of novel Nanomedical platforms and Nano drugs. Nanomedicine is a branch of nanotechnology which includes the development of nano-structures and nano-analytical systems for various medical applications. Many diseases originate from the alterations at nano scale level. The drug delivery should be achieved not only at the cell level

Global Microcapsules Drug Delivery Market Opportunity & Future Outlook 2022

The tremendous progress of biotechnology and nanotechnology in the past 30 years has resulted in a whole new generation of drug delivery regimens. With significant paradigm shifts in drug discovery and development, the industry is also gearing up to adopt alternative drug delivery strategies in order to further facilitate drug development. Opportunities have significantly increased in the last few years. Pharmaceutical companies are collaborating with drug delivery firms to effectively

Global Dendritic Cell Cancer Vaccine Market & Dendritic Cell Cancer Vaccine Clin …

Dendritic cell first discovered in the early 19th century by Paul Langerhans and their further study and the role it plays in immune system conducted by M. Steinman in 1973, has only received the must deserved attention as a vaccine molecule, in general and as a cancer therapeutics, in particular in the recent past years. There was a widespread skepticism regarding its potential as a vaccine in the scientific community

Asia Battery Energy Storage Market Overview 2017-2020

Across the world, efforts are underway to improve the way to store and distribute energy, as electricity generation mix is shifting towards more sustainable but intermittent forms of energy generation, such as wind and solar power. The rapid growth in variable renewable energy is catalyzing efforts to modernize the electricity system. At high levels of penetration, variable renewable energy increases the need for resources that contribute to system flexibility. This

India Nuclear Power Sector Investment Opportunity Outlook 2032

India started its journey in nuclear programme shortly after getting independence by setting up Atomic Energy Commission in August 1948 to look after atomic energy activities in the country. In order to consolidate all the research and development activity for nuclear reactors and technology under the Atomic Energy Commission, The Government of India created the Atomic Energy Establishment, Trombay (AEET) on 3 January 1954 as the premier research institution for

Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022

Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways

Global Oncolytic Virus Therapy Market & Oncolytic Virus clinical Trials Outlook …

Advancements in human genomics over the last two decades have shown that cancer is mediated by somatic aberration in the host genome. This discovery has incited enthusiasm among cancer researchers; many now use therapeutic approaches in genetic manipulation to improve cancer regression and find a potential cure for the disease. The dominant cancer treatment modalities such as chemotherapy, radiotherapy, and even targeted kinase inhibitors and mAbs are limited by low

Global Cancer Nanomedicine Market & Cancer Nanomedicine Clinical Trials Outlook …

Over the past several years, many innovative and revolutionary techniques have been developed in order to treat cancer. These techniques range from basic surgical removal to X-ray irradiation to system wide flooding with anticancer agents. However, each of these approaches has its own series of undesirable side effects that are both dangerous and damaging to the overall health of the patient. On the contrary, very recent breakthroughs in nanomedicine have

Global Cancer Immunotherapy Market & Cancer Immunotherapy Clinical Trials Outloo …

Pharmaceutical companies are actively engaged in research and development of cancer immunotherapies because of large unmet medical necessities. Investigators are trying to come forth with innovative cancer immunotherapeutic products having high safety and efficacy profiles which are not offered by conventional therapeutics. Higher investments in research and development segment could significantly increase the drug discovery rates which will alleviate the medical condition of cancer patients. Simultaneously, technological advancements are being

Global Cancer Antibody Drug Conjugates Market & Cancer ADC Clinical Pipeline Ins …

Cancer incidences are rapidly escalating across the globe due to which high unmet medical necessities have been felt. Pharmaceutical companies have introduced innovative therapeutics for the cancer treatment which belongs to different drug categories. They have made significant investments in research and development for offering better medical care. ADCs are new addition to the cancer therapeutic segment which is already overcrowded and consists of numerous competitors. ADCs are based on

Global Controlled Drug Delivery Market & Controlled Drug Delivery Clinical Trial …

With significant paradigm shifts in drug discovery and development, the industry is also gearing up to adopt alternative drug delivery strategies in order to further facilitate drug development. Opportunities have significantly increased in the last few years. Pharmaceutical companies are collaborating with drug delivery firms to effectively target patient concerns. Many different drug delivery systems have been designed and evaluated, and a large number of strategies for site-specific drug targeting

Global Cell Therapy Market & Cell Therapy Clinical Pipeline Outlook 2022

The cell therapy industry is rapidly growing industry with the several new products that having been accepted for clinical use over the past few years. There are many challenges that need to be resolved wisely before the cell therapies are widely accepted, including the optimization of their manufacture. There is much to be explored about the specific features of the stem cells and about the efficacy and safety of the

Global Car T Cell Therapy Market Outlook and Car T Cell Therapy Clinical Trials …

The research in immunotherapy has unlocked the way to harness an individual’s immune response to fight against the tumors and cancers. Many of the ideas have tried to make the use of natural killer cells or B cell, however, the research has not moved a past conceptual thinking. Immuno-oncology is an evolving treatment modality with the agents which being studied for their potential to provide the long term survival across

EMA grants orphans drug status to Therabron Therapeutics’ CG367

March 1, 2017 Orphan Drug European Medicine Agency has awarded Therabron Therapeutics, a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care; with Orphan drug Designation for its leading product candidate, CG367, for the treatment of patients with Bronchiolitis Obliterans Syndrome (BOS). BOS is extremely serious and life threatening combination of lung transplantation, which generally manifests between 18 months to four years after the procedure. Additionally, the

FDA grants orphan drug designation to lysogene’s LYSGM101 for GM1 Gangliosidos …

US Food and Drug Association has designated LYGSM101 as orphan drug, developed by Lysogene, a clinical stage biotechnology company focused on developing gene therapy for rare central nervous system diseases, for the treatment of GM1 Gangliosidosis. LY-GSM101 is the company’s leading gene therapy candidate. Action of mechanism for the novel gene therapy, LYGSM101 is to replace the defective genes in the cells of patients suffering from GM1 Gangliosidosis to allow production

FDA grants orphan drug designation to sickle cell treatment

Imara therapeutics, a leading biopharmaceutical announced that US Food and Drug Administration have granted orphan drug designation to its novel drug, IMR-657 to treat patients with Sickle cell disease. Presently, IMR-657 is stepping towards its first clinical phase to investigate its safety and pharmo-kinetics in patients with sickle cell. The study is currently being examined over patients between the ages of 18-55 years having sickle cell. IMR-687 is an orally-administered selective

Abeona receives orphan drug designation for ABO-101 to treat Sanfilippo Syndrome …

Abeona therapeutics, a clinical stage bio-pharmaceutical company dedicated to develop gene therapies for life threatening diseases, has recently announced that its novel gene therapy candidate, ABO-101 has been awarded with orphan drug status for the treatment of children with Sanfilippo Syndrome Type-B, by the European Medicine Agency (EMA), a committee for orphan medicinal products. Sanfilippo Syndrome Type-B is a rare genetic disease causing neurocognitive decline, speech loss, loss of mobility,

Idogen receives orphan drug status for Hemophilia A

European Commission has granted orphan drug designation to Idogen for the treatment of patients with Hemophilia A. The European Commission grants orphan drug designation status to provide incentives to develop medicinal products to treat, prevent or diagnose diseases or conditions that affect no more than five in 10,000 persons in the European Union. The orphan drug designation provides Abeona with incentives and benefits in the EU, including protocol assistance, reduced

Arthritis in Children gets orphan drug by FDA

US Food and Drug Administration has granted orphan drug designation to an oral liquid suspension of celecoxib for the treatment of children suffering from pediatric juvenile idiopathic arthritis. The liquid suspension is developed and formulated by a clinical stage biopharmaceutical company, NuBioPharma, LLC. Nu-Celecoxib has been developed within flavors for children enabling measurement of precise doses that can easily be administered. Juvenile Idiopathic Arthritis (JIA) is the most common type

EC grants orphan drug designation to Therabron Therapeutic’s CG367

Therabron Therapeutics has recently announced that European Union has awarded its leading drug candidate, CG367 with orphan drug designation for the treatment of Bronchiolitis Obliterans Syndrome. Previously CG367 has been granted orphan drug status by US Food and Drug Administration. The FDA and EMA’s designation of orphan status is granted to encourage new developments and therapies for rare diseases and disorders. Orphan Status can be applied to products proven safe and

ONCURIOUS NV receives orphan drug status for TB-403 for Medulloblastoma

Oncurious NV, an oncology development company dedicated to develop innovative orphan drugs for the treatment of pediatric tumors, has received orphan drug designation for its novel product, TB-403 from European Medicine Agency (EMA) for the treatment of patients with Medulloblastoma. TB-403 is currently being examined in a Phase I/II a clinical trial for treatment of medulloblastoma, a pediatric cancer. TB-403 is a humanized monoclonal antibody against placental growth factor (PlGF).

NH Therapeutics receives orphan drug designation for congenital hypogonadotropic …

NH Therapeutics, a biopharmaceutical company that focuses on developing drugs and therapies for effective treatment of rare neuroendocrine disorders, recently announced that European Medicine Agency has awarded its leading drug candidate NH-901 with orphan drug designation for the treatment of congenital hypogonadotropic hypogonadism. NH901 is a reformulation of a GnRH analogue, which has been repurposed to increase gonadotropins, sex hormones and boost fertility. The Stichting Centre for Human Drug Research

FDA grants orphan drug status to Vicore

US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug

FDA grants orphan drug designation to Sangamo’s SB-318

Sangamo Biosciences Inc., a biopharmaceutical company announced that US Food and Drug Administration has granted orphan drug designation to its genome editing candidate, SB-319 for the treatment of Mucopolysaccharidosis Type I (MPS I), a rare lysosomal storage disorder. FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and

Yeliva receives FDA orphan drug status for cholangiocarcinoma

US Food and Drug Administration has granted orphan drug designation to Yeliva a first-in-class, orally administered, sphingosine kinase-2 selective inhibitor with anticancer and anti-inflammatory activities, for the effective treatment of cholangiocarcinoma. The drug is developed by RedHill Biopharma. The investigation suggested that the drug is well endured and can be safely administered to patients suffering from the disease. The action of mechanism for Yeliva includes circulation in the patient’s body

EU Commission grants orphan drug designation to Abeona’s EB101 Gene Therapy

Abeona Therapeutics, a leading pharmaceutical company recently announced that European Medicine Agency has granted orphan drug designation to its leading gene therapy candidate, EB 101 for effective treatment of patient with Epidermolysis Bullosa. Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating, life-threatening genetic skin disorder that is characterized by skin blisters and erosions all over the body. The ongoing phase 1/2 clinical trial with gene-corrected skin grafts has shown promising wound

ChemoCentryx announces FDA orphan drug designation for Avacopan in the Treatment …

US Food and Drug Administration (FDA) have announced orphan drug designation for chemocentryx’s leading product candidate, avacopan for the treatment of patients suffering with Debilitating Kidney Disease C3 Glomerulopathy (C3G). ChemoCentryx, Inc. is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. C3G is a severe kidney disease characterized by deposits of proteins from the body’s complement system into and around the kidney’s filtration units, the

Go To Page: 1 2 3 4 5 6 7 8 10 12 13 14 15 16 17